KYMERA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Accrued Liabilities of $6.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $13.49M, a 183.96% increase year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$7.21M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $13.66M, a 51.43% increase year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $664.00K, a 75.85% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $7.39M, a 76.72% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $4.18M, a 31.45% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $3.18M, a 29.63% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $4.52M, a 64.13% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.28M 10-Q · filed 2026-08-05 | $19.94M derived: sum of 3 quarters · filed 2026-08-05 | $20.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$7.21M 10-Q · filed 2026-04-30 | $6.45M derived: sum of 2 quarters · filed 2026-04-30 | $7.12M derived: sum of 3 quarters · filed 2026-04-30 | $11.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $13.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.33M derived: sum of 2 quarters · filed 2026-02-26 | $19.08M derived: sum of 3 quarters · filed 2026-08-05 | $7.39M 10-K · filed 2026-02-26 |
| 2025-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.42M derived: sum of 2 quarters · filed 2026-08-05 | -$6.28M 10-Q · filed 2025-11-04 | $2.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$6.94M 10-Q · filed 2026-08-05 | $2.08M derived: sum of 3 quarters · filed 2026-08-05 | $4.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.69M 10-Q · filed 2026-04-30 | -$2.67M derived: sum of 2 quarters · filed 2026-04-30 | $81.00K derived: sum of 3 quarters · filed 2026-04-30 | $7.88M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.77M derived: sum of 2 quarters · filed 2026-02-26 | $19.57M derived: sum of 3 quarters · filed 2026-02-26 | $4.18M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.55M derived: sum of 2 quarters · filed 2025-11-04 | -$4.84M 10-Q · filed 2025-11-04 | $1.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$7.59M 10-Q · filed 2025-08-11 | -$798.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$15.39M 10-Q · filed 2025-05-09 | -$8.60M derived: sum of 2 quarters · filed 2026-02-26 | -$5.96M derived: sum of 3 quarters · filed 2026-02-26 | -$2.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.43M derived: sum of 2 quarters · filed 2026-02-26 | $13.22M derived: sum of 3 quarters · filed 2026-02-26 | $3.18M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $6.42M derived: sum of 2 quarters · filed 2024-10-31 | -$3.61M 10-Q · filed 2024-10-31 | -$771.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$6.25M 10-Q · filed 2024-08-07 | -$3.41M derived: sum of 3 quarters · filed 2025-02-27 | -$13.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$10.04M 10-Q · filed 2024-05-02 | -$7.20M derived: sum of 2 quarters · filed 2025-02-27 | -$3.80M derived: sum of 3 quarters · filed 2025-02-27 | -$3.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.24M derived: sum of 2 quarters · filed 2025-02-27 | $6.80M derived: sum of 3 quarters · filed 2025-02-27 | $4.52M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.96M derived: sum of 2 quarters · filed 2023-11-02 | $1.68M 10-Q · filed 2023-11-02 | $5.47M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $558.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.72M 10-Q · filed 2023-08-03 | $2.08M derived: sum of 3 quarters · filed 2024-02-22 | $6.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$2.28M 10-Q · filed 2023-05-04 | $1.52M derived: sum of 2 quarters · filed 2024-02-22 | $6.23M derived: sum of 3 quarters · filed 2024-02-22 | $10.09M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $8.51M derived: sum of 2 quarters · filed 2024-02-22 | $12.36M derived: sum of 3 quarters · filed 2024-02-22 | $12.60M 10-K · filed 2024-02-22 |
| 2021-09-30 | $4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.57M derived: sum of 2 quarters · filed 2022-11-03 | $8.80M 10-Q · filed 2022-11-03 | $12.29M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $3.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.09M 10-Q · filed 2022-08-09 | $7.58M derived: sum of 3 quarters · filed 2023-02-23 | $6.71M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $235.00K 10-Q · filed 2022-05-03 | $3.72M derived: sum of 2 quarters · filed 2023-02-23 | $2.85M derived: sum of 3 quarters · filed 2023-02-23 | $5.30M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.62M derived: sum of 2 quarters · filed 2023-02-23 | $5.06M derived: sum of 3 quarters · filed 2023-02-23 | $5.75M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$868.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.58M derived: sum of 2 quarters · filed 2021-11-10 | $2.27M 10-Q · filed 2021-11-10 | $1.83M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $3.14M 10-Q · filed 2021-08-06 | $2.70M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $690.00K 10-Q · filed 2021-05-06 | $252.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.25M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $2.69M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |